

1 **Diagnostic accuracy of the Panbio™ COVID-19 Antigen rapid test device for** 2 **SARS-CoV-2 detection in Kenya, 2021: A field evaluation**

3 **Authors**

4 Irungu Karuga¹, Peninah Munyua², Caroline Ochieng³, Bonventure Juma², Patrick Amoth⁴,
5 Francis Kuria⁴, John Kiiru⁴, Lyndah Makayotto⁴, Ahmed Abade¹, Marc Bulterys², Elizabeth
6 Hunsperger², Gideon O. Emukule², Clayton Onyango², Taraz Samandari², Beth A. Tippet Barr²,
7 Victor Akelo², Herman Weyenga², Patrick K Munywoki², Godfrey Bigogo³, Nancy A. Otieno³,
8 Jackton Azenga Kisivuli⁵, Edwin Ochieng⁶, Rufus Nyaga⁶, Noah Hull⁶, Amy Herman-Roloff²,
9 and Rashid Aman⁴

10 **Author affiliations**

- 11 1. *Field Epidemiology and Laboratory Training Program, Ministry of Health, Kenya*
- 12 2. *U.S. Centers for Disease Control and Prevention, Kenya (CDC)*
- 13 3. *Kenya Medical Research Institute (KEMRI), Center for Global Health Research*
- 14 4. *Ministry of Health, Kenya*
- 15 5. *Kenya Prisons Service, Directorate of Health*
- 16 6. *Association of Public Health Laboratories (APHL)*

17 **Corresponding author;** Irungu Karuga **email:** jkarugah@gmail.com

18 **Abstract**

19 **Background:** Accurate and timely diagnosis is essential in limiting the spread of severe acute
20 respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Real-time reverse transcription-
21 polymerase chain reaction (rRT-PCR), the reference standard, requires specialized laboratories,
22 costly reagents, and a long turnaround time. Antigen rapid diagnostic tests (Ag RDTs) provide a

23 feasible alternative to rRT-PCR since they are quick, relatively inexpensive, and do not require a
24 laboratory. The WHO requires that Ag RDTs have a sensitivity 80% and specificity 97%.

25 **Methods:** This evaluation was conducted at 11 health facilities in Kenya between March and
26 July 2021. We enrolled persons of any age with respiratory symptoms and asymptomatic
27 contacts of confirmed COVID-19 cases. We collected demographic and clinical information and
28 two nasopharyngeal specimens from each participant for Ag RDT testing and rRT-PCR. We
29 calculated the diagnostic performance of the Panbio™ Ag RDT against the US Centers for
30 Disease Control and Prevention's (CDC) rRT-PCR test.

31 **Results:** We evaluated the Ag RDT in 2,245 individuals where 551 (24.5%, 95% CI: 22.8-
32 26.3%) tested positive by rRT-PCR. Overall sensitivity of the Ag RDT was 46.6% (95% CI:
33 42.4-50.9%), specificity 98.5% (95% CI: 97.8-99.0%), PPV 90.8% (95% CI: 86.8-93.9%) and
34 NPV 85.0% (95% CI: 83.4-86.6%). Among symptomatic individuals, sensitivity was 60.6%
35 (95% CI: 54.3-66.7%) and specificity was 98.1% (95% CI: 96.7-99.0%). Among asymptomatic
36 individuals, sensitivity was 34.7% (95% CI 29.3-40.4%) and specificity was 98.7% (95% CI:
37 97.8-99.3%). In persons with onset of symptoms <5 days (594/876, 67.8%), sensitivity was
38 67.1% (95% CI: 59.2-74.3%), and 53.3% (95% CI: 40.0-66.3%) among those with onset of
39 symptoms >7 days (157/876, 17.9%). The highest sensitivity was 87.0% (95% CI: 80.9-91.8%)
40 in symptomatic individuals with cycle threshold (Ct) values 30.

41 **Conclusion:** The overall sensitivity and NPV of the Panbio™ Ag RDT were much lower than
42 expected. The specificity of the Ag RDT was high and satisfactory; therefore, a positive result
43 may not require confirmation by rRT-PCR. The kit may be useful as a rapid screening tool for
44 only symptomatic patients in high-risk settings with limited access to RT-PCR. A negative result

45 should be interpreted based on clinical and epidemiological information and may require

46 retesting by rRT-PCR.

47 **Keywords: SARS-CoV-2, COVID-19 testing, rapid antigen test, diagnostic tests, Panbio™,**

48 **symptomatic, asymptomatic, evaluation**

49

50 Introduction

51 The COVID-19 pandemic has had major negative socioeconomic effects. Prompt diagnosis of
52 SARS-CoV-2 infection is critical in controlling the pandemic. Real-time reverse transcription-
53 polymerase chain reaction (rRT-PCR) remains the reference standard for the diagnosis of SARS-
54 CoV-2 infection. However, rRT-PCR has limitations, including the need for specialized
55 laboratory, equipment, and staff, longer turnaround time (TAT) for clinical decision making and
56 prevention measures, high cost, and erratic supply of reagents to conduct SARS-CoV-2 rRT-
57 PCR due to increased demand (1,2). These limitations have increased the demand for more rapid,
58 cheaper, and easy to perform testing methods.

59 Antigen rapid diagnostic tests (Ag RDTs) increase patients' access to diagnosis of SARS-CoV-2
60 infection. The World Health Organization (WHO) recommends Ag RDTs with a minimum
61 sensitivity and specificity 80% and 97%, respectively where rRT-PCR is unavailable or is
62 associated with long TAT (3).

63 We evaluated the performance of the Panbio™ Ag RDT compared to the reference standard
64 rRT-PCR. The Panbio™ Ag RDT is authorized in Kenya and received an emergency use license
65 (EUL) from WHO (4). We also assessed the operational characteristics of the Panbio™ Ag RDT
66 in the field setting.

67 Methods

68 We conducted a prospective cross-sectional evaluation of the Panbio™ Ag RDT in 11 sites in
69 Kenya between March and July 2021. The sites were located in Nairobi County (Nairobi remand
70 Prison, Langata Women's Prison, and Tabitha level 2 Clinic), Kiambu County (Kihara Sub-
71 county Hospital), Nakuru County (Nakuru Prison), Nyeri County (Nyeri level 5 Hospital and

72 Nyeri Prison), Kisumu County (Kisumu Prison-Kodiaga), Mombasa County (Coast General
73 Teaching and Referral Hospital) and Siaya County (Siaya County Referral Hospital and St.
74 Elizabeth Mission Hospital). The protocol was reviewed and approved by the Kenya Medical
75 Research Institute's (KEMRI) scientific ethical review unit (SERU). The US Centers for Disease
76 Control and Prevention (CDC) institutional review board provided non-research determination
77 approval. Further administrative approvals were obtained from the Ministry of Health Kenya, the
78 National Commission for Science, Technology, and Innovation (NACOSTI) Kenya, the Kenya
79 Prisons Service, and the county governments of Nakuru, Nyeri, Mombasa, Kiambu, and Siaya.
80 Written informed consent was obtained for all enrolled participants. Written parental informed
81 consent and assent were obtained for participants aged <18 years.

82 [Clinical case definition for enrollment](#)

83 We enrolled persons of any age who presented to our study sites with respiratory symptoms
84 (symptomatic participants) that met any of three case definitions, including acute respiratory
85 infection (ARI,) defined as cough or difficulty in breathing or sore throat or coryza, with the
86 onset of symptoms <2 weeks; severe acute respiratory infection (SARI) defined as fever or
87 temperature $\geq 38^{\circ}\text{C}$ and cough, with onset of symptoms <10 days and requiring hospitalization;
88 or influenza-like illness (ILI) defined as temperature $\geq 38^{\circ}\text{C}$ and cough, with onset of symptoms
89 <10 days. Body temperature measurement was done using infrared thermometers placed 3 to 5
90 centimeters from the temple. We also enrolled asymptomatic close contacts of individuals with
91 confirmed SARS-CoV-2 infection exposed between two days before and 14 days after symptoms
92 onset or confirmation of infection. Individuals exposed to persons with confirmed SARS-CoV-2
93 infection in the following setups were considered close contacts in the following scenarios:
94 working in close proximity or sharing the same environment; face-to-face contact within 1 meter

95 for more than 15 minutes; traveling together in any kind of conveyance; living in the same
96 household; healthcare-associated exposure, including providing direct care for COVID-19
97 patients, visiting patients or staying in the same close environment.

98 [Data and specimen collection](#)

99 Individuals who met the case definition and consented were enrolled and assigned unique
100 identifiers. We collected demographic information, and clinical information via electronic
101 questionnaires on smartphones. Data was stored in a secured cloud server. Clinical information
102 collected included the range and duration of respiratory symptoms, presence of comorbidities,
103 and reported history of exposure to confirmed COVID-19. Two nasopharyngeal swabs were
104 collected by a surveillance officer [nurse, clinical officer, or laboratory technologist] trained to
105 collect respiratory specimens from each of the nostrils a few seconds apart. The first specimen
106 was collected using the swab provided in the Panbio™ Ag RDT kit. The second specimen was
107 collected using a polyester-tipped aluminum shafted swab and immediately placed in viral
108 transport media at +2 to +8°C and shipped to the CDC-supported KEMRI laboratories in
109 Nairobi or Kisumu for rRT-PCR testing where long-term storage was done at -80°C.

110 [Rapid SARS-CoV-2 antigen testing](#)

111 Rapid testing was conducted using the Panbio™ Ag RDT (Abbott Rapid Diagnostics, US. Ref.
112 41FK10) per manufacturer instructions by surveillance officers. The Panbio™ Ag RDT is a
113 lateral flow immunoassay that detects the nucleocapsid (N) protein in nasal and nasopharyngeal
114 specimens(5). Results were read and documented independently by two surveillance officers
115 within 15 to 20 minutes. Positive, negative, and invalid results were interpreted according to the
116 manufacturer's recommendations. Each reader documented the test results in the electronic

117 questionnaire independently. In the event the two readers documented different results, the final
118 result was indicated as indeterminate.

119 [Assessing the operational characteristics of the Panbio™ Ag RDT kit](#)

120 We assessed operational characteristics of the Panbio™ Ag RDT in the field setting including
121 clarity of kit instructions, technical complexity or ease of use, and the ease of interpretation of
122 results via a standardized questionnaire administered to users on site.

123 [RT-PCR testing in the Laboratory](#)

124 According to the manufacturer's instructions, total nucleic acid material was extracted from
125 200µL of the nasopharyngeal specimen using either the Ambion MagMax Total RNA isolation
126 kit (Thermo Fisher Scientific, Greenville, North Carolina, USA) performed on a semi-automated
127 KingFisher flex machine (Thermo Fisher Scientific) or Standard M Spin-X Viral RNA
128 Extraction Kit (SD biosensor) according to the manufacturer's instructions. We then eluted 60uL
129 of total RNA from the extracted sample. The SARS-CoV-2 rRT-PCR was performed using the
130 TaqPath 1-step Multiplex rRT-PCR master mix (Thermo Fisher Scientific) or using the GoTaq®
131 Probe 1-Step RT-qPCR System (Promega A6120). Both systems are compatible with the rRT-
132 PCR CDC IDT kit. Each of the 15µL reaction volumes contained 5µL of master mix, 8.5µL of
133 nuclease-free water, and 1.5µL of CDC-IDT primer/probe mix for each of the N1, N2, and RNP3
134 genes separately. The eluate was then amplified using QuantStudio™ 5 Real-Time PCR System,
135 0.1ml block (Thermo Fisher Scientific), and analyses were done using QuantStudio 3 and 5 Real-
136 Time PCR System Software version 1.5.1 (Thermo Fisher Scientific). SARS-CoV-2 assay
137 targets, N1 and N2 (N1 and N2) were run simultaneously with the human ribonuclease P gene
138 (RNP) control to monitor the quality of the nucleic acid extraction, specimen quality, and

139 presence of reaction inhibitors for assay performance. The positive, negative, and human
140 specimen controls were included in all assays.

141 RT-PCR testing

142 When all controls exhibited expected performance, a positive result for SARS-CoV-2 was
143 considered, if all assay amplification curves crossed the threshold line within Ct <40. If SARS-
144 CoV-2 (N1 and N2) assay results were negative, then the test result was reported as negative. If
145 only one target (N1 and N2) were positive, then it was designated as inconclusive, and retesting
146 was conducted. If upon repeating the test, the results remain inconclusive, then the final result
147 was reported as inconclusive. Results were relayed back to the specific sites for patient
148 management.

149 Sample size calculation

150 To evaluate the diagnostic performance of the Panbio™ Ag RDT device, we assumed a
151 prevalence of 10% among symptomatic individuals and 5% in asymptomatic contacts of
152 laboratory-confirmed persons based on current SARS CoV 2 local surveillance data. We
153 assumed a sensitivity of 90% for the Panbio™ Ag RDT with 7.5% margin of error, and after
154 adjusting by 10% for other concerns we anticipated enrolling 770 symptomatic patients and
155 1,540 close contacts of confirmed cases.

156 Statistical analysis

157 Statistical analysis was conducted using Stata version 15.1 (College Station, Texas). Measures of
158 central tendency and dispersion were calculated for continuous variables such as age, days since
159 onset of symptoms, temperature, and cycle threshold (Ct) values. We calculated frequencies and
160 proportions for categorical variables such as age group, occupation, and Ct value cut-offs. The

161 95% confidence intervals for categorical variables were calculated using the normal
162 approximation method (Wald's test). We compared proportions between the symptomatic and
163 asymptomatic groups by calculating their Z scores. P-values <0.05 were considered statistically
164 significant.

165 We calculated the sensitivity, specificity, and positive and negative predictive values for the
166 Panbio™ Ag RDT against rRT-PCR as the reference standard. Stratified analysis of performance
167 was done by age, day's post-onset of symptoms, and Ct values. The measure of agreement
168 between Ag RDT and rRT-PCR results was evaluated using Cohen's Kappa statistic. We
169 interpreted the strength of agreement as slight agreement (, 0 0.2), fair (, 0.21 0.4), moderate
170 (, 0.41 0.6), substantial (, 0.61 0.8), and almost perfect (, 0.81 1.0) as described by Landis *et*
171 *al.* (6).

172

173 Results

174 *Enrolled participant characteristics*

175 We enrolled 2,279 participants, where 38.9% had at least one respiratory symptom. The median
176 age was 31.0 years, and over half (60.9%) were male (Table 1). The median duration post-onset
177 of symptoms among symptomatic participants was three days, with the majority (67.8%)
178 presenting within 5 days.

179 *Table 1: Clinical and demographic characteristics of participants in the field evaluation of the*
180 *Panbio™ Ag RDT in Kenya, 2021*

181 Laboratory findings

182 Panbio™ Ag RDT test results

183 Among the 2,277 tested using the Panbio™ Ag RDT device, 12.4% were positive (Fig 1). There
184 were no invalid or indeterminate Ag RDT results. The positivity was significantly higher among
185 symptomatic individuals (18.7%) compared with the asymptomatic (8.4%,) individuals.

186 *Fig 1: Flow diagram of enrolment of study participants and distribution by clinical status and*
187 *test results in the field evaluation of the Panbio™ Ag RDT in Kenya, 2021*

188 rRT PCR test results

189 We tested 2,277 specimens by rRT-PCR, 24.2% tested positive and 1.4% were inconclusive.
190 Positivity (28.7%,) was higher among symptomatic participants compared to asymptomatic
191 (21.4%) ones. Among the 32 inconclusive rRT-PCR results, 22 (68.8%) were from
192 asymptomatic individuals, and 31 (96.9%) tested negative by Ag RDT (Fig 1). The overall
193 median Ct value of the 551 rRT-PCR positive results was 30.2 (IQR 22.9-35.6). Symptomatic

194 individuals had a significantly lower median Ct value of 26.2 compared to 33.0 among
195 asymptomatic individuals ($p < 0.001$). The median Ct value was significantly lower among those
196 with Ag RDT positive results (23.2) compared to negative test results (35.1) ($p < 0.001$) (**Error!**
197 **Reference source not found.**).

198 *Error! Reference source not found.*

199 *Performance of Panbio™ Ag RDT*

200 We reviewed 2,245 paired Ag RDT/rRT-PCR records for the performance analysis. The overall
201 sensitivity of the Panbio™ Ag RDT was 46.6% and specificity was 98.5% (Table 2). At the
202 observed SARS-CoV-2 prevalence (24.5%) the positive predictive value (PPV) was 90.8% and
203 the negative predictive value (NPV) was 85.0% (Table 2; S1 Fig and S2 Fig). The overall
204 agreement between the Ag RDT and rRT-PCR results was moderate ($k=0.5$), substantial ($k=0.7$)
205 among the symptomatic, and fair ($k=0.4$) among the asymptomatic. The performance of the
206 Panbio™ Ag RDT is summarized in Table 2.

207 *Table 2: The performance of the Panbio™ Ag RDT by clinical status, and Ct value*

208 Among the symptomatic participants who were positive for SARS-CoV-2 by rRT-PCR, 100
209 (39.4%) had a false negative result by Ag RDT. Two percent (12/632) who were negative for
210 SARS-CoV-2 by RT-PCR had a false positive result by Ag RDT. Among the asymptomatic
211 individuals, 65.3% (n=194) had a false negative Ag RDT result, and 1.3% (n=14) had a false
212 positive result by Ag RDT.

213 Among the 876 symptomatic participants, the sensitivity was 60.6% (95% CI: 54.3-66.7%) (S3
214 Fig). Sensitivity in those with days post onset of symptoms < 5 was 67.1% and declined to 53.3%
215 among those with onset > 7 days. Among the asymptomatic, sensitivity was significantly lower at

216 34.7% (95% CI: 29.3-40.4%) compared to symptomatic individuals ($p < 0.001$). Specificity
217 remained high in symptomatic (98.1%, 95% CI: 96.7-99.0%) and asymptomatic individuals
218 (98.7%, 95% CI: 96.7-99.0%) (S4 Fig).

219 Regardless of the presence or absence of symptoms, the overall sensitivity of the Ag RDT test in
220 273 specimens with Ct values ≤ 30 was 81.3% (95% CI: 72.2-91.6). This reduced to 12.6% (95%
221 CI: 11.2-14.2%) among the 278 individuals with Ct > 30 (Table 2).

222 [Evaluation of the user's experience of the Panbio™ Ag RDT](#)

223 A total of 17 surveillance officers comprising 10 (59%) clinicians and 7 (41%) laboratory staff
224 completed the survey. All 17(100%) surveillance officers found the test procedure easy to
225 perform, and the manufacturers' instructions were found to be clear and easy to follow. Four
226 (23.5%) of the surveillance officers noted the difficulty in dispensing a sample onto the test
227 device from the extraction tube when nasopharyngeal specimens were collected from individuals
228 with thick mucus.

229 [Discussion](#)

230 We present findings of a field evaluation of the Panbio™ Ag RDT conducted among both
231 symptomatic patients with onset of symptoms up to 14 days and asymptomatic individuals who
232 had contact with individuals with confirmed SARS-CoV-2 infection within two days before
233 detection of the index case and up to 14 days after exposure. Our evaluation was conducted in
234 the third COVID-19 wave in Kenya(7,8).

235 The overall sensitivity was low (46.6%), detecting slightly less than half of the rRT-PCR
236 confirmed cases, therefore, missing more than half and classifying them as not having SARS-
237 CoV-2 infection when they were indeed infected. The overall sensitivity we report was lower

238 than observed in studies that enrolled both symptomatic and asymptomatic individuals in a
239 multicenter study in Spain conducted among individuals of any age (57.3%, 95%CI: 48.3-95.8%)
240 (9), Spanish adults in primary care centers (71.4%, 95% CI: 63.1-78.7%) (10), among Spanish
241 individuals of any age (73.3 %, 95 % CI: 62.2–83.8%) (11), and persons of any age presenting
242 within 7 days of onset or exposure (90.5%, 95% CI 87.5-93.6%) (12).

243 The low overall sensitivity observed may be due to the high proportion (61.1%) of asymptomatic
244 participants, and the higher Ct values we observed in these individuals. The lower performance
245 could also be due to the relatively younger (median age 31 years) population we enrolled
246 compared to other studies we reviewed where the median age was higher (39-51.5 years)
247 (11,13). A recent study demonstrated increasing viral load with increasing age (14); higher
248 sensitivities have been observed among individuals with higher viral loads compared to lower
249 ones. The alpha variant and delta variants predominated our evaluation in Kenya (15,16). While
250 some literature indicates that variants of concern (17,18) do not reduce the sensitivity and
251 specificity of Ag RDTs, a recent study revealed that sensitivity of the Panbio™ Ag RDT
252 declined significantly in individuals infected with the alpha variant (53.0%) compared to those
253 with non-alpha variants (89.0%) even after adjusting for viral load ($p < 0.002$) (19). Mutations
254 occurring in the N protein of the Alpha variant may not be detected by the Panbio™ Ag RDT
255 (20).

256 The sensitivity among symptomatic individuals (60.6%) was lower than the WHO
257 recommendation of 80% (21). The sensitivity among symptomatic individuals with onset of
258 symptoms within 7 days was also lower than that reported by the manufacturer on specimens
259 tested on nasopharyngeal specimens (61.6% vs. 91.1%) (5). This is possibly due to the use of
260 specimens with high viral loads by the manufacturer's study for approval as hypothesized by

261 *Albert et al., 2021* in an evaluation where SARS-CoV-2 cultures were done (1). Similar
262 sensitivity was observed in symptomatic Mexican adults (58.1%, 95% CI: 54.9-61.3%) (22).
263 However, the sensitivity we observed among symptomatic individuals was higher compared to
264 that reported in a multicenter evaluation conducted among symptomatic children (60.6% vs.
265 45.4%) with the onset of symptoms within five days (13).

266 In our evaluation, sensitivity was higher among symptomatic individuals compared to
267 asymptomatic ones (60.6% vs. 34.7%). Similar findings were observed in other evaluations with
268 higher sensitivity among symptomatic individuals compared to asymptomatic in a study in
269 Mexico (58.1% vs. 26.3%) (22), in Spain (80.4% vs. 56.6%) (10), among Greek children (95.2%
270 vs. 22.2%) (23), and among Swiss children (73% vs. 43%) (24). However, a German study found
271 similar sensitivities between the two groups (86.8% vs. 85.7%) (25).

272 Individuals with Ct value ≤ 30 had higher sensitivity compared to those with Ct value >30 , as
273 observed in other evaluations of Panbio™ Ag RDT (11). The same has been observed in other
274 evaluations considering Ct values ≤ 30 (25–27). We also observed higher viral loads among
275 symptomatic individuals (median Ct = 26.2) compared to asymptomatic individuals (median Ct
276 = 33.0) from our evaluation ($p < 0.001$). Similar findings have also been reported recently
277 (28,29). In contrast, some studies found no difference in viral load between the two groups
278 (30,31,) while others found higher viral load among asymptomatic individuals (32,33). Higher
279 sensitivity has been observed among individuals presenting in the early symptomatic phase of
280 their infection (12,22,25–27,34–36). While rRT-PCR testing for SARS-CoV-2 is the reference
281 standard for diagnosis limited access to molecular tests in our setting and provision of results in a
282 clinically relevant timely manner to inform case management limits their clinical utility.
283 Therefore, given reasonable sensitivity, individuals with a negative test in an individual meeting

284 the clinical and epidemiological criteria may require a confirmatory test by RT-PCR. The
285 variation in sensitivity by presence or absence of symptoms, symptom duration, and viral load
286 indicates that the kit may only be useful among individuals with high viral loads, especially those
287 with symptoms.

288 The PPV (90.8%) observed at the prevalence of SARS-CoV-2 infection of 24.5% by rRT-PCR
289 was similar to the projected PPV (89.6%) assuming the minimum recommended sensitivity
290 (80%) and specificity (97.0%). The NPV (85.0%) was lower compared to that computed (93.7%)
291 assuming the minimum recommendations. Among individuals who tested negative by Ag RDT,
292 the likelihood of being wrongly classified as uninfected was 15%. In 2021, the median positivity
293 rate in Kenya was 7.4% (IQR, 3.2-13.1%) (37). At the observed sensitivity and specificity and
294 the national positivity rate, PPV would range between 50.2% and 82.8%, and the NPV 92.4% -
295 98.2%).

296 The overall specificity we observed (98.5%) was high and was above the WHO recommendation
297 for both symptomatic and asymptomatic individuals and across the other subgroups (21) and was
298 similar to observations in similar evaluations (22,25,26,35,38–41). The Ag RDT had high
299 specificity with less than (1.5%) of the tests (n=26) giving a false-positive result. This small
300 proportion represents individuals who would be falsely classified as infected and unnecessarily
301 be managed as COVID-19 cases or self-isolated and their contacts traced and quarantined.

302 However, we observed over half (53%) of the Ag RDT results gave false-negative results with a
303 higher proportion (65%) among the asymptomatic individuals. This observation emphasizes the
304 recommendation by WHO to re-test symptomatic patients with rRT-PCR when they receive a
305 negative Ag RDT result, especially in settings where SARS-CoV-2 prevalence is 5%. Further,
306 as a screening tool for testing contacts of confirmed cases, the 65% false negatives among

307 asymptomatic contacts represent the proportion that would falsely be classified as virus-free, not
308 self-isolate, and potentially infect others.

309 The Panbio™ Ag RDT was found to be easy to use by the majority of the users with a quick
310 TAT for clinical decision making and implementation of preventive measures to contain
311 transmission as observed in the literature (25,26). The main challenge we observed in conducting
312 Ag RDT testing using the Panbio™ Ag RDT kits was dispensing the specimen onto the test
313 device in samples collected from individuals with thick mucus. This was, however, solved by
314 ensuring that individuals blew their noses before specimen collection.

315 Our field evaluation had several strengths. The evaluation was conducted in the real-world
316 setting across multiple sites under the point-of-care conditions which had a large sample size
317 comprising two groups (symptomatic and asymptomatic individuals) thereby representing
318 individuals at any point of the COVID-19 disease spectrum.

319 Limitation: The number of persons enrolled in the two groups, symptomatic and asymptomatic,
320 may not reflect the true prevalence in the general population as we evaluated the Ag RDT during
321 a period of high COVID-19 prevalence.

322 Conclusion

323 The overall sensitivity and PPV of the Panbio™ Ag RDT were much lower than expected.
324 Sensitivity was acceptable in symptomatic individuals with Ct value \leq 30. Specificity of the Ag
325 RDT was high and satisfactory; therefore, a positive result may not require confirmation by rRT-
326 PCR. The kit may be useful as a rapid screening tool for only symptomatic patients in high-risk

327 settings with limited access to RT-PCR. A negative result should be interpreted based on clinical
328 and epidemiological information and may require retesting by rRT-PCR.

329 Acknowledgment

330 We acknowledge all the study participants, surveillance officers, and laboratory staff that
331 participated in this evaluation. In addition, we thank the Ministry of Health Kenya, the Kenya
332 Prisons Service, Washington State University (WSU) Global Health Kenya, and the County
333 departments of Health of Kiambu, Mombasa, Nakuru, Nyeri, and Siaya for the continued support
334 throughout the implementation of the evaluation.

335 Funding

336 This project was supported through Cooperative Agreement Number NU2HGH000032, funded
337 by the US Centers for Disease Control and Prevention to the Association for Public Health
338 Laboratories (APHL). Its contents are solely the responsibility of the authors and do not
339 necessarily represent the official views of the US Centers for Disease Control and Prevention or
340 the Department of Health and Human Services.

341 Conflict of interest

342 The authors declare no conflict of interest.

343 Disclaimer: The findings and conclusions in this report are those of the author(s) and do not
344 necessarily represent the official position of the U.S. Centers for Disease Control and Prevention.
345 Use of trade names is for identification only and does not imply endorsement by [the Centers for
346 Disease Control and Prevention/the Agency for Toxic Substances and Disease Registry], the
347 Public Health Service, or the U.S. Department of Health and Human Services

348 References

- 349 1. Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernández-Fuentes MÁ, et al. Field
350 evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for
351 COVID-19 diagnosis in primary healthcare centres. *Clin Microbiol Infect* [Internet]. 2021
352 Mar;27(3):472.e7-472.e10. Available from:
353 <https://linkinghub.elsevier.com/retrieve/pii/S1198743X20306972>
- 354 2. Barra GB, Rita THS, Mesquita PG, Jácomo RH, Nery LFA. Overcoming supply shortage
355 for SARS-CoV-2 detection by RT-qPCR. *Genes (Basel)*. 2021;12(1):1–10.
- 356 3. World Health Organization (WHO). Antigen-detection in the diagnosis of SARS-CoV-2
357 infection using rapid immunoassays Interim guidance, 11 September 2020. *World Heal*
358 *Organ* [Internet]. 2020;(September):1–9. Available from:
359 [https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-](https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays%0Ahttps://apps.who.int/iris/handle/10665/334253)
360 [2infection-using-rapid-immunoassays%0Ahttps://apps.who.int/iris/handle/10665/334253](https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays%0Ahttps://apps.who.int/iris/handle/10665/334253)
- 361 4. World Health Organization (WHO). WHO Emergency Use Listing for In vitro diagnostics
362 (IVDs) Detecting SARS-CoV-2. Geneva [Internet]. World Health Organization (WHO).
363 Geneva; 2020. Available from:
364 [https://extranet.who.int/pqweb/sites/default/files/documents/210217_eul_sars-](https://extranet.who.int/pqweb/sites/default/files/documents/210217_eul_sars-cov2_product_list.pdf%0Ahttps://www.who.int/diagnostics_laboratory/201002_eul_sars-cov2_product_list.pdf?ua=1)
365 [cov2_product_list.pdf%0Ahttps://www.who.int/diagnostics_laboratory/201002_eul_sars_](https://extranet.who.int/pqweb/sites/default/files/documents/210217_eul_sars-cov2_product_list.pdf%0Ahttps://www.who.int/diagnostics_laboratory/201002_eul_sars-cov2_product_list.pdf?ua=1)
366 [cov2_product_list.pdf?ua=1](https://extranet.who.int/pqweb/sites/default/files/documents/210217_eul_sars-cov2_product_list.pdf?ua=1)
- 367 5. Abbott. Panbio™ Test Device COVID-19 Ag Rapid -In vitro diagnostic rapid test for
368 qualitative detection of SARS-CoV-2 antigen (Ag) [Internet]. 2021. Available from:
369 [https://dam.abbott.com/en-gb/panbio/120007883-v1-Panbio-COVID-19-Ag-Nasal-](https://dam.abbott.com/en-gb/panbio/120007883-v1-Panbio-COVID-19-Ag-Nasal-AsymptomaticSe.pdf)
370 AsymptomaticSe.pdf
- 371 6. Landis JR, Koch GG. The Measurement of Observer Agreement for Categorical Data.
372 *Biometrics* [Internet]. 1977 Mar;33(1):159. Available from:
373 <https://www.jstor.org/stable/2529310?origin=crossref>
- 374 7. Ministry of Health Kenya. Covid-19 Outbreak in Kenya Situation report 670. Vol. 670.
375 2021.

- 376 8. World Health Organization W. WHO Coronavirus Disease (COVID-19) Dashboard With
377 Vaccination Data | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data
378 [Internet]. World Health Organization. 2022 [cited 2022 Feb 20]. Available from:
379 <https://covid19.who.int/region/afro/country/ke>
- 380 9. Agulló V, Fernández-González M, Ortiz de la Tabla V, Gonzalo-Jiménez N, García JA,
381 Masiá M, et al. Evaluation of the rapid antigen test Panbio COVID-19 in saliva and nasal
382 swabs in a population-based point-of-care study. *J Infect*. 2021;82(5):186–230.
- 383 10. Bulilete O, Lorente P, Leiva A, Carandell E, Oliver A, Rojo E, et al. Panbio™ rapid
384 antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary
385 health care. *J Infect* [Internet]. 2021 Mar;82(3):391–8. Available from:
386 <https://doi.org/10.1016/j.jinf.2021.02.014>
- 387 11. Linares M, Pérez-Tanoira R, Carrero A, Romanyk J, Pérez-García F, Gómez-Herruz P, et
388 al. Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7
389 days after the onset of symptoms. *J Clin Virol* [Internet]. 2020 Dec;133(January):104659.
390 Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1386653220304017>
- 391 12. Merino P, Guinea J, Muñoz-Gallego I, González-Donapetry P, Galán JC, Antona N, et al.
392 Multicenter evaluation of the Panbio™ COVID-19 rapid antigen-detection test for the
393 diagnosis of SARS-CoV-2 infection. *Clin Microbiol Infect*. 2021;27(5):758–61.
- 394 13. Villaverde S, Domínguez-Rodríguez S, Sabrido G, Pérez-Jorge C, Plata M, Romero MP,
395 et al. Diagnostic Accuracy of the Panbio Severe Acute Respiratory Syndrome Coronavirus
396 2 Antigen Rapid Test Compared with Reverse-Transcriptase Polymerase Chain Reaction
397 Testing of Nasopharyngeal Samples in the Pediatric Population. *J Pediatr* [Internet]. 2021
398 May;232(January):287-289.e4. Available from:
399 <https://linkinghub.elsevier.com/retrieve/pii/S0022347621000342>
- 400 14. Euser S, Aronson S, Manders I, van Lelyveld S, Herpers B, Sinnige J, et al. SARS-CoV-2
401 viral-load distribution reveals that viral loads increase with age: a retrospective cross-
402 sectional cohort study. *Int J Epidemiol* [Internet]. 2022 Jan 6;50(6):1795–803. Available
403 from: <https://academic.oup.com/ije/article/50/6/1795/6366466>

- 404 15. KEMRI. Genomic surveillance detects local transmission of the global variants of concern
405 in nine counties in Kenya. 2021.
- 406 16. Kimita G, Nyataya J, Omuseni E, Sigei F, Lemtudo A, Muthanje E, et al. A genomics
407 dissection of Kenya's COVID-19 waves: temporal lineage replacements and dominance of
408 imported variants of concern. 2021; Available from:
409 <https://www.researchsquare.com/article/rs-942627/v1>
- 410 17. Bekliz M, Adea K, Essaidi-Laziosi M, Sacks JA, Escadafal C, Kaiser L, et al. SARS-
411 CoV-2 rapid diagnostic tests for emerging variants. *The Lancet Microbe* [Internet].
412 2021;2(8):e351. Available from: [http://dx.doi.org/10.1016/S2666-5247\(21\)00147-6](http://dx.doi.org/10.1016/S2666-5247(21)00147-6)
- 413 18. Bekliz M, Adea K, Essaidi-Laziosi M, Sacks JA, Escadafal C, Kaiser L, et al. SARS-
414 CoV-2 antigen-detecting rapid tests for the delta variant. *The Lancet Microbe* [Internet].
415 2022 Feb;3(2):e90. Available from: [http://dx.doi.org/10.1016/S2666-5247\(21\)00302-5](http://dx.doi.org/10.1016/S2666-5247(21)00302-5)
- 416 19. van Ogtrop ML, van de Laar TJW, Eggink D, Vanhommerig JW, van der Reijden WA.
417 Comparison of the Performance of the PanBio COVID-19 Antigen Test in SARS-CoV-2
418 B.1.1.7 (Alpha) Variants versus non-B.1.1.7 Variants. Wesley Long S, editor. *Microbiol*
419 *Spectr* [Internet]. 2021 Dec 22;9(3):1–22. Available from:
420 <https://journals.asm.org/doi/10.1128/Spectrum.00884-21>
- 421 20. Jian MJ, Chung HY, Chang CK, Lin JC, Yeh KM, Chen CW, et al. SARS-CoV-2 variants
422 with T135I nucleocapsid mutations may affect antigen test performance. *Int J Infect Dis*
423 [Internet]. 2022;114:112–4. Available from: <https://doi.org/10.1016/j.ijid.2021.11.006>
- 424 21. World Health Organization. SARS-CoV-2 Antigen detecting rapid diagnostic test
425 implementation projects [Internet]. 2020. p. 1–6. Available from:
426 [https://www.who.int/news-room/articles-detail/sars-cov-2-antigen-detecting-rapid-](https://www.who.int/news-room/articles-detail/sars-cov-2-antigen-detecting-rapid-diagnostic-test-implementation-projects)
427 [diagnostic-test-implementation-projects](https://www.who.int/news-room/articles-detail/sars-cov-2-antigen-detecting-rapid-diagnostic-test-implementation-projects)
- 428 22. Thirion-Romero I, Guerrero-Zúñiga DS, Arias-Mendoza DA, Cornejo-Juárez DDP, Meza-
429 Meneses DP, Torres-Erazo DDS, et al. Evaluation of Panbio rapid antigen test for SARS
430 CoV 2 in symptomatic patients and their contacts: a multicenter study. *Int J Infect Dis*
431 [Internet]. 2021 Dec;113:218–24. Available from:

- 432 <https://linkinghub.elsevier.com/retrieve/pii/S1201971221008110>
- 433 23. Eleftheriou I, Dasoula F, Dimopoulou D, Lebessi E, Serafi E, Spyridis N, et al. Real-life
434 evaluation of a COVID-19 rapid antigen detection test in hospitalized children. *J Med*
435 *Virool.* 2021;93(10):6040–4.
- 436 24. L’Huillier AG, Lacour M, Sadiku D, Gadiri MA, De Siebenthal L, Schibler M, et al.
437 Diagnostic accuracy of sars-cov-2 rapid antigen detection testing in symptomatic and
438 asymptomatic children in the clinical setting. *J Clin Microbiol.* 2021;59(9):1–8.
- 439 25. Krüger LJ, Gaeddert M, Tobian F, Lainati F, Gottschalk C, Klein JAF, et al. The Abbott
440 PanBio WHO emergency use listed, rapid, antigen-detecting point-of-care diagnostic test
441 for SARS-CoV-2—Evaluation of the accuracy and ease-of-use. Mantis NJ, editor. *PLoS*
442 *One* [Internet]. 2021 May 27;16(5):e0247918. Available from:
443 <https://dx.plos.org/10.1371/journal.pone.0247918>
- 444 26. FIND. FIND Evaluation of Abbott Panbio COVID-19 Ag Rapid Test Device External
445 Report. 2020;(December):1–4. Available from: [https://www.finddx.org/wp-](https://www.finddx.org/wp-content/uploads/2020/12/Panbio_Ag-Public-Report_v2.1.pdf)
446 [content/uploads/2020/12/Panbio_Ag-Public-Report_v2.1.pdf](https://www.finddx.org/wp-content/uploads/2020/12/Panbio_Ag-Public-Report_v2.1.pdf)
- 447 27. Alemany A, Baró B, Ouchi D, Rodó P, Ubals M, Corbacho-Monné M, et al. Analytical
448 and clinical performance of the panbio COVID-19 antigen-detecting rapid diagnostic test.
449 *J Infect* [Internet]. 2021 May;82(5):186–230. Available from:
450 <https://linkinghub.elsevier.com/retrieve/pii/S0163445321000050>
- 451 28. Almadhi MA, Abdulrahman A, Sharaf SA, AlSaad D, Stevenson NJ, Atkin SL, et al. The
452 high prevalence of asymptomatic SARS-CoV-2 infection reveals the silent spread of
453 COVID-19. *Int J Infect Dis* [Internet]. 2021;105:656–61. Available from:
454 <https://doi.org/10.1016/j.ijid.2021.02.100>
- 455 29. Strutner J, Ramchandar N, Dubey S, Gamboa M, Vanderpool MK, Mueller T, et al.
456 Comparison of Reverse-Transcription Polymerase Chain Reaction Cycle Threshold
457 Values From Respiratory Specimens in Symptomatic and Asymptomatic Children With
458 Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *Clin Infect Dis* [Internet].
459 2021 Nov 16;73(10):1790–4. Available from:

- 460 <https://academic.oup.com/cid/article/73/10/1790/6266745>
- 461 30. Zuin M, Gentili V, Cervellati C, Rizzo R, Zuliani G. Viral load difference between
462 symptomatic and asymptomatic COVID-19 patients: Systematic review and meta-
463 analysis. *Infect Dis Rep*. 2021;13(3):645–53.
- 464 31. Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio C, et
465 al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. *Nature*
466 [Internet]. 2020 Aug 20;584(7821):425–9. Available from:
467 <http://www.nature.com/articles/s41586-020-2488-1>
- 468 32. Cardillo L, de Martinis C, Viscardi M, Esposito C, Sannino E, Lucibelli G, et al. SARS-
469 CoV-2 quantitative real time PCR and viral loads analysis among asymptomatic and
470 symptomatic patients: an observational study on an outbreak in two nursing facilities in
471 Campania Region (Southern Italy). *Infect Agent Cancer*. 2021;16(1):1–7.
- 472 33. Hasanoglu I, Korukluoglu G, Asilturk D, Cosgun Y, Kalem AK, Altas AB, et al. Higher
473 viral loads in asymptomatic COVID-19 patients might be the invisible part of the iceberg.
474 *Infection* [Internet]. 2021;49(1):117–26. Available from: [https://doi.org/10.1007/s15010-](https://doi.org/10.1007/s15010-020-01548-8)
475 [020-01548-8](https://doi.org/10.1007/s15010-020-01548-8)
- 476 34. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral
477 shedding and transmissibility of COVID-19. *Nat Med*. 2020;26(5):672–5.
- 478 35. Berger A, Nsoga MTN, Perez-Rodriguez FJ, Aad YA, Sattonnet-Roche P, Gayet-Ageron
479 A, et al. Diagnostic accuracy of two commercial SARSCoV- 2 antigen-detecting rapid
480 tests at the point of care in community-based testing centers. *PLoS One*. 2021;16(3 March
481 2021):1–12.
- 482 36. Ferté T, Ramel V, Cazanave C, Lafon M-E, Bébéar C, Malvy D, et al. Accuracy of
483 COVID-19 rapid antigenic tests compared to RT-PCR in a student population: The
484 StudyCov study. *J Clin Virol* [Internet]. 2021 Aug;141(January):104878. Available from:
485 <https://linkinghub.elsevier.com/retrieve/pii/S1386653221001451>
- 486 37. Hasell J, Mathieu E, Beltekian D, Macdonald B, Giattino C, Ortiz-Ospina E, et al. A
487 cross-country database of COVID-19 testing. *Sci Data* [Internet]. 2020 Dec 8 [cited 2022

- 488 Feb 20];7(1):345. Available from: <https://ourworldindata.org/coronavirus-testing>
- 489 38. Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernández-Fuentes MÁ, et al. Field
490 evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for
491 COVID-19 diagnosis in primary healthcare centres. *Clin Microbiol Infect* [Internet].
492 2021;27(3):472.e7-472.e10. Available from: <https://doi.org/10.1016/j.cmi.2020.11.004>
- 493 39. Christensen A, Larsdatter M, Landaas E, Bragstad K, Kran A-MB, Tollånes M, et al.
494 Evaluation of Abbot's Panbio COVID -19 rapid antigen test in Norway [Internet]. 2020.
495 Available from: [https://www.helsedirektoratet.no/rapporter/evaluation-of-abbots-panbio-](https://www.helsedirektoratet.no/rapporter/evaluation-of-abbots-panbio-covid-19-rapid-antigen-test-in-norway/Evaluation%20of%20Abbotts%20Panbio%20COVID-19%20rapid%20antigen%20test%20in%20Norway.pdf/_/attachment/inline/b3306b98-c0e0-4e96-aa62-3ca5a99f5367:10fe6f072721ece7aee)
496 [covid-19-rapid-antigen-test-in-norway/Evaluation of Abbots Panbio COVID-19 rapid](https://www.helsedirektoratet.no/rapporter/evaluation-of-abbots-panbio-covid-19-rapid-antigen-test-in-norway/Evaluation%20of%20Abbotts%20Panbio%20COVID-19%20rapid%20antigen%20test%20in%20Norway.pdf/_/attachment/inline/b3306b98-c0e0-4e96-aa62-3ca5a99f5367:10fe6f072721ece7aee)
497 [antigen test in Norway.pdf/_/attachment/inline/b3306b98-c0e0-4e96-aa62-](https://www.helsedirektoratet.no/rapporter/evaluation-of-abbots-panbio-covid-19-rapid-antigen-test-in-norway/Evaluation%20of%20Abbotts%20Panbio%20COVID-19%20rapid%20antigen%20test%20in%20Norway.pdf/_/attachment/inline/b3306b98-c0e0-4e96-aa62-3ca5a99f5367:10fe6f072721ece7aee)
498 [3ca5a99f5367:10fe6f072721ece7aee](https://www.helsedirektoratet.no/rapporter/evaluation-of-abbots-panbio-covid-19-rapid-antigen-test-in-norway/Evaluation%20of%20Abbotts%20Panbio%20COVID-19%20rapid%20antigen%20test%20in%20Norway.pdf/_/attachment/inline/b3306b98-c0e0-4e96-aa62-3ca5a99f5367:10fe6f072721ece7aee)
- 499 40. Torres I, Poujois S, Albert E, Colomina J, Navarro D. Evaluation of a rapid antigen test
500 (Panbio™ COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic
501 close contacts of COVID-19 patients. *Clin Microbiol Infect* [Internet]. 2021
502 Apr;27(4):636.e1-636.e4. Available from:
503 <https://linkinghub.elsevier.com/retrieve/pii/S1198743X20307825>
- 504 41. Dinnes J, Deeks JJ, Berhane S, Taylor M, Adriano A, Davenport C, et al. Rapid, point-of-
505 care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. *Cochrane*
506 *Database Syst Rev* [Internet]. 2021 Mar 24;2021(4). Available from:
507 <http://doi.wiley.com/10.1002/14651858.CD013705.pub2>
- 508
- 509

510 Tables

511 *Table 1: Clinical and demographic characteristics of participants in the field evaluation of the Panbio™ Ag RDT in Kenya, 2021*

Variable	Symptomatic (886) n (%)	Asymptomatic (1,393) n (%)	Total (2,279) n (%)	P-value
Sex				
Male	510 (57.6)	877 (63.0)	1387 (60.9)	0.01
Female	376 (42.4)	516 (37.0)	892 (39.1)	0.01
Symptoms				
Cough	604 (68.4)	-	-	-
Fever	294 (33.2)	-	-	-
Runny nose	266 (30.1)	-	-	-
Headache	231 (26.2)	-	-	-
Sore throat	197 (22.2)	-	-	-
Shortness of breath	195 (22.0)	-	-	-
Duration since onset				
<5 days	601 (67.8)	-	-	
5- 7 days	126 (14.2)	-	-	
7-14 days	159 (18.0)	-	-	
>7 days	814 (91.9)	-	-	
>7-14 days	72 (8.1)	-	-	
Comorbidities and underlying conditions				
Cardiovascular disease, including hypertension	87 (9.8)	13 (0.9)	100 (4.4)	<0.001
Immunodeficiency, including HIV	31 (3.5)	25 (1.8)	56 (2.5)	0.011
Diabetes	18 (2.0)	6 (0.4)	24 (1.1)	<0.001
Other conditions	43 (4.7)	34 (2.3)	77 (3.2)	0.002
No known comorbidities	720 (81.1)	1266 (90.4)	1986 (86.8)	<0.001
Other risk factors				
Smoking (current or former smoker)	11 (1.2)	53 (3.8)	64 (2.8)	<0.001
Occupational settings				
Inmates and prison warders	265 (29.8)	1034 (73.9)	1299 (56.8)	<0.001
Health care workers	72 (8.1)	109 (7.8)	181 (7.9)	0.942
Learning institutions	103 (11.6)	64 (4.6)	167 (7.3)	0.123
Preschool	117 (13.2)	21 (1.5)	138 (6)	0.945
Other employment	287 (32.3)	171 (12.2)	458 (20.1)	<0.001
Missing	44 (5)	1 (0.1)	45 (2)	-

512 n, number of; HIV, human immunodeficiency virus

513 Table 2: The performance of the Panbio™ Ag RDT by clinical status, and Ct value

	<i>n</i>	Ag RDT +ve	rRT-PCR +ve	Ag RDT -ve	rRT-PCR -ve	Sensitivity % (95% CI)	Specificity % (95% CI)	PPV % (95% CI)	NPV % (95% CI)	Kappa k (95% CI)
Cases										
<i>All</i>	2,245	257	551	1,668	1,694	46.6 (42.4-50.9)	98.5 (97.8-99.0)	90.8 (86.8-93.9)	85.0 (83.4-86.6)	0.5 (0.5-0.6)
<i>Symptomatic</i>	876	154	254	610	622	60.6 (54.3-66.7)	98.1 (96.7-99.0)	92.8 (87.7-96.2)	85.9 (83.1-88.4)	0.7 (0.6-0.7)
<i>Asymptomatic</i>	1,369	103	297	1,058	1,072	34.7 (29.3-40.4)	98.7 (97.8-99.3)	88.0 (80.7-93.3)	84.5 (82.4-86.5)	0.4 (0.4-0.5)
Days post onset of symptom										
<5 days	594	106	158	428	436	67.1 (59.2-74.3)	98.2 (96.4-99.2)	93.0 (86.6-96.9)	89.2 (86.0-91.8)	0.7 (0.6-0.8)
5-7 days	125	16	36	87	89	44.4 (27.9-61.9)	97.8 (92.1-99.7)	88.9 (65.3-98.6)	81.3 (72.6-88.2)	0.5 (0.3-0.7)
>7-14 days	157	32	60	95	97	53.3 (40.0-66.3)	97.9 (92.7-99.7)	94.1 (80.3-99.3)	77.2 (68.8-84.3)	0.6 (0.4-0.7)
7 days	805	146	237	557	568	61.6 (55.1-67.8)	98.1 (96.6-99.0)	93.0 (87.8-96.5)	86.0 (83.0-88.5)	0.7 (0.6-0.7)
>7-14 days	71	8	17	53	54	47.1 (23.0-72.2)	98.1 (90.1-100.0)	88.9 (51.8-99.7)	85.5 (74.2-93.1)	0.5 (0.3-0.8)
Ct value 30										
<i>All</i>	273	222	273	-	-	81.3 (72.2-91.6)	-	-	-	-
<i>Symptomatic</i>	162	141	162	-	-	87.0 (80.9-91.8)	-	-	-	-
<i>Asymptomatic</i>	111	81	111	-	-	73.0 (60.6-87.9)	-	-	-	-
Ct value >30 - <40										
<i>All</i>	278	35	278	-	-	12.6 (11.2-14.2)	-	-	-	-
<i>Symptomatic</i>	92	13	92	-	-	14.1 (7.7-23.0)	-	-	-	-
<i>Asymptomatic</i>	186	22	186	-	-	11.8 (10.2-13.7)	-	-	-	-

514 n, number of; Ag RDT, antigen rapid diagnostic test; CI, confidence interval; PPV, positive predictive value; NPV, negative

515 predictive value; Ct, cycle threshold

516 Figures





Fig 1: Flow diagram of enrolment of study participants and distribution by clinical status and test results in the field evaluation of the Panbio™ Ag RDT in Kenya, 2021

517 Ag RDT, Antigen rapid diagnostic test; rRT-PCR, real-time reverse transcriptase-polymerase
 518 chain reaction




519

520 Fig 2: Distribution of Cycle threshold (Ct) values for rRT-PCR positive samples by Ag RDT
521 result and by presence/absence of symptoms, Kenya 2021 (n=551)


522 Ag RDT, Antigen rapid diagnostic test; Ct, cycle threshold

523 Supporting information



524


525 S1 Fig: The Positive Predictive Value of the Panbio™ Ag RDT by clinical status and days post onset of symptoms, Kenya 2021



526


527 S2 Fig: The Negative Predictive Value of the Panbio™ Ag RDT by clinical status and days post onset of symptoms, Kenya 2021

528



529

530 *S3 Fig: The sensitivity of the Panbio™ Ag RDT by clinical status, and Ct values*



531

532 *S4 Fig: The specificity of the Panbio™ Ag RDT by clinical status and days post onset of symptoms, Kenya 2021*